Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Impact of autoimmune disease on toxicity and outcomes after idecabtagene vicleucel in patients with multiple myeloma.

Rebecca Albuquerque, Anna Shamis, Athanasios Tsalatsanis et al. Jun 01, 2025 pp. 7552-7552 10.1200/jco.2025.43.16_suppl.7552

7552 Background: Idecabtagene vicleucel (ide-cel), an autologous BCMA-directed chimeric antigen receptor (CAR) T-cell therapy, has the potential to cure p...

Alcohol use and liver cancer mortality in the U.S. (1999–2020): A CDC WONDER analysis.

Izzah Nayyab, Najam Gohar, Faizan Ahmed et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13535

e13535 Background: Alcohol consumption is a major risk factor for liver cancer, contributing to preventable mortality. This study examines trends in U.S....

Multicenter trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) with monthly adjuvant temozolomide for patients with high-grade gliomas.

Graeme Woodworth, Pavlos Anastasiadis, Chetan Bettegowda et al. Jun 01, 2025 pp. 2009-2009 10.1200/jco.2025.43.16_suppl.2009

2009 Background: High-grade gliomas (HGGs) have few effective therapies targeting tumor cell recurrence, which remain shielded by blood-brain barrier (BBB...

Chemo-praidict eBC: A deep learning solution for predicting pathological complete response on biopsies of breast cancer patients treated with neoadjuvant chemotherapy.

Sylvain Ladoire, Natalia Valderrama, Louis-Oscar Morel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15156

e15156 Background: In precision medicine, the prediction of tumor chemosensitivity is of major importance to offer cancer patients the best possible treat...

Efficacy and safety of distamab vedotin combined with carboplatin and bevacizumab for HER2-expressing platinum-sensitive ovarian cancer with prior PARPi treatment.

Huijuan Yang, Wei Jiang, Xuan Pei et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17580

e17580 Background: Disitamab Vedotin (DV) is a newly developed antibody-drug conjugate targeting human epidermal growth factor 2 (HER2) that is comprised...

Effect of oral mucositis on nutrition among patients with head and neck cancer.

Ifeyinwa Carol Onwukeme, Enomfon Paul Okure Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18123

e18123 Background: Cancer encompasses a vast array of diseases characterised by the uncontrolled division of abnormal cells that have the potential to inf...

Association of total neoadjuvant therapy sequencing with surgical intervention and overall survival in locally advanced rectal cancer: An NCDB analysis.

Insija Ilyas Selene, Feitong Lei, Bin Huang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15630

e15630 Background: Pooled analyses of the CAO/ARO/AIO-12 and OPRA trials in locally advanced rectal cancer (LARC) suggest that chemoradiotherapy followed...

First accounting of comprehensive radiotherapy life cycle assessment components in Africa.

Phylicia Gawu, Charles Akoto-Aidoo, Isaac Washburn et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23213

e23213 Background: Climate change is a pressing issue on the global stage. Recently a comprehensive lifecycle assessment (LCA) of external beam radiothera...

Efficacy and safety of busulfan-fludarabine versus busulfan-cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: A meta-analysis of randomized controlled trials and observational studies.

Aizaz Ali, Muhammad Abdullah Ali, Abdullah Afridi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18546

e18546 Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for hematologic malignancies but comes with risks...

Clear and non-clear cell renal cell carcinomas and the ability to engage in oxidative phosphorylation.

Ziad Bakouny, Sonia Boscenco, Ruobing Cui et al. Jun 01, 2025 pp. 4542-4542 10.1200/jco.2025.43.16_suppl.4542

4542 Background: The impairment of oxidative phosphorylation (OxPhos) and upregulation of aerobic glycolysis, mediated by the loss of VHL...

Navigating healthcare costs and family support: Coping strategies adopted by breast cancer patients in a tertiary cancer care center—A qualitative phenomenological analysis.

Krishna Priya, Rajkumar Kottayasamy Seenivasagam, Sashi Ranjani et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21022

e21022 Background: Economic distress caused by high costs of cancer treatment poses a significant challenge to patients and their caregivers. It affects t...

Outcomes with targeted therapy for NRAS-mutated melanoma: A systematic review and meta-analysis.

Abat Khan, Nouman Aziz, Umar Akram et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21506

e21506 Background: Despite advancements in targeted therapy, NRAS-mutated melanoma remains a significant therapeutic challenge. This meta-analysis aims to...

Breast cancer survivors' perspectives on a clinical decision tool to facilitate individualized exercise prescriptions within clinical settings.

Oliver W.A. Wilson, Kaitlyn M. Wojcik, Eleanor M. Kerr et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13715

e13715 Background: Current clinical guidelines recommend that clinicians provide individualized exercise prescriptions to cancer survivors. However, there...

Radiotherapy integration strategy for small-cell lung cancer in extensive stage (RISE) with up to 10 metastases: A study protocol of a randomized phase II trial.

Łukasz Kuncman, Jacek Fijuth, Damian Tworek et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps8125

TPS8125 Background: The standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) currently involves chemo-immunotherapy...

Melanoma dormancy: Predictors of relapse in resected early-stage cutaneous melanoma.

Ilias Christodoulou, Cindy Sander, Shuaichao Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21557

e21557 Background: Early-stage (IA, IB, IIA) cutaneous melanoma (CM) is treated with wide local excision (WLE). However, some patients (PTS) relapse (R),...

Limited versus expanded multigene germline genetic testing among adolescents and young adults (AYA) with breast cancer.

Baha' Sharaf, Hira Bani Hani, Faris Tamimi et al. Jun 01, 2025 pp. 10588-10588 10.1200/jco.2025.43.16_suppl.10588

10588 Background: In low- and middle-income countries, like ours, breast cancer is diagnosed mostly in younger women. With a median age of 50-52 years, br...

EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).

Michail Ignatiadis, Emmanouil S. Saloustros, Ana Joaquim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps620

TPS620 Background: (Neo)adjuvant systemic treatment, with chemotherapy and/or endocrine therapy (ET), substantially reduces the recurrence rates of estrog...

AI-driven risk stratification for disease progression after allo-SCT in AML.

Hiffsa Taj, Reuben Adatorwovor, Nick Trosper et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18562

e18562 Background: Disease progression is the leading cause of allogeneic stem cell transplantation (allo-SCT) failure in acute myeloid leukemia (AML). Ou...

Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors.

Yuehong Kong, Shicheng Li, Meiling Xu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14606

e14606 Background: Severe lymphopenia remains a significant obstacle to the long-term success of immunotherapy. In combination therapies, radiation-induce...

Clinical outcomes of patients with stage I triple-negative breast cancer (TNBC) treated with or without chemotherapy: The Mayo Clinic experience.

Sumeet Kumar Yadav, Sarah K. Reed, David Zahrieh et al. Jun 01, 2025 pp. 548-548 10.1200/jco.2025.43.16_suppl.548

548 Background: TNBC is associated with higher risk of recurrence and poorer survival rates than other breast cancer subtypes. For node-positive TNBC or t...

Disparities in health-related quality of life between low-income Latino and white men with prostate cancer.

Victoria E. Rodriguez, Lorna Kwan, Jiayue Chen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23187

e23187 Background: Prostate cancer is the second most common cancer and the most diagnosed cancer among Latino men in the United States. Advances in scree...

Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction of outcomes across immunotherapy regimens in NSCLC: An external validation study.

Vamsidhar Velcheti, Young Kwang Chae, Kai Zhang et al. Jun 01, 2025 pp. 8581-8581 10.1200/jco.2025.43.16_suppl.8581

8581 Background: Tumor angiogenesis is critical to cancer progression and treatment resistance, as evidenced by the success of therapies targeting both im...

Mutations in homologous recombination DNA damage repair genes and treatment outcomes to immune checkpoint inhibitors in melanomas.

Priya Katyal, Sach Thakker, Micah Belzberg et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21502

e21502 Background: Homologous recombination DNA damage repair (HR-DDR) gene mutations are frequently found in melanomas, and studies have shown the presen...

Clinical characteristics and prognostic factors for survival in metastatic osteosarcoma, a 2004-2021 retrospective analysis of cases in SEER.

Ahmad Al Shihabi, Fizza Mohsin, Sabina Sayeed et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23512

e23512 Background: Osteosarcoma is the most common primary bone malignancy, and 20% of cases are metastatic at diagnosis. Previous studies analyzing data...

Innovative data visualization tool for tracking system failures in colorectal cancer screening.

John Hunting, Corey Obermiller, Lauren Witek et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13598

e13598 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S., yet 30% of Americans are not up to date with...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page